Expansion of ST2-expressing macrophages in a patient with bronchiolitis obliterans syndrome
Open Access
- 30 March 2023
- journal article
- letter
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (3)
Abstract
Bronchiolitis obliterans syndrome (BOS) is a major complication of haematopoietic stem cell transplantation (HSCT), which affects the lungs and has limited treatment options [1]. BOS after HSCT is considered a manifestation of chronic graft-versus-host disease (GVHD). T-cells play a crucial role in its onset [2], while the contribution of myeloid cells has been largely unknown.Keywords
Funding Information
- Japan Agency for Medical Research and Development
- Boehringer Ingelheim
- the Kakihara Foundation
This publication has 9 references indexed in Scilit:
- Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseasesFrontiers in Immunology, 2023
- Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitisBlood Advances, 2023
- Reprogramming alveolar macrophage responses to TGF-β reveals CCR2+ monocyte activity that promotes bronchiolitis obliterans syndromeJournal of Clinical Investigation, 2022
- T Cell Subsets in Graft Versus Host Disease and Graft Versus TumorFrontiers in Immunology, 2021
- IL-33-ST2 axis regulates myeloid cell differentiation and activation enabling effective club cell regenerationNature Communications, 2020
- The ST2/IL-33 Axis in Immune Cells during Inflammatory DiseasesFrontiers in Immunology, 2017
- Obliterative BronchiolitisNew England Journal of Medicine, 2014
- ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and DeathNew England Journal of Medicine, 2013
- IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway InflammationThe Journal of Immunology, 2009